| Business Summary | | Cardiome
Pharma
Corporation,
formerly
known
as
Nortran
Pharmaceuticals
Inc.,
is
a
drug
discovery
company
engaged
in
the
treatment
of
pathologies
and
conditions
which
are
mediated
by
cellular
ion
channels.
The
Company's
primary
focus
is
the
discovery
and
development
of
drugs
designed
to
prevent
cardiac
arrhythmias
and
for
the
treatment
of
acute
unproductive
cough.
To
date,
the
Company
has
not
yet
determined
the
ultimate
economic
viability
of
the
drugs
and
has
not
commenced
commercial
operations
for
its
drugs. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Cardiome
Pharma
Corp.
is
a
pharmaceutical
company
whose
primary
focus
is
the
development
of
targeted
small
molecules
for
the
treatment
of
life-threatening
cardiac
arrhythmias.
For
the
six
months
ended
5/31/01,
revenues
rose
22%
to
C$357
thousand.
Net
loss
rose
62%
to
C$4.1
million.
Revenues
reflect
higher
grant
income
and
increased
interest
income
due
to
higher
average
cash
balances.
Higher
loss
reflects
increased
costs
related
to
the
RSD
1235
clinical
trial. | More
from
Market Guide: Significant
Developments |
| Officers | | | FY1999 Pay | |
| Michael Walker, Ph.D. Chairman | -- | Robert Rieder Pres,
CEO | $200K | Gregory Beatch VP
- Research | 125K | Sheila Grant Sec. of Fin. and Admin. | -- | Dollar
amounts are as of 30-Nov-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|